GENB AS |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.3 USD | +61.49% |
|
+0.50% | +10.11% |
| May. 15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
| May. 15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.8B 2.88B | Sales 2025 * | 23.62B 3.44B | Capitalization | 132B 19.18B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 681M | Net income 2025 * | 6.63B 965M | EV / Sales 2024 * | 5.33 x |
| Net cash position 2024 * | 26.36B 3.83B | Net cash position 2025 * | 33.63B 4.89B | EV / Sales 2025 * | 4.16 x |
| P/E ratio 2024 * |
29.9
x | P/E ratio 2025 * |
21.5
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on GENB AS
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +7.52% | 115B | |
| +12.72% | 107B | |
| -13.44% | 22.31B | |
| -3.99% | 21.6B | |
| -6.38% | 18.23B | |
| -39.93% | 17.62B | |
| +6.91% | 14.26B | |
| +32.76% | 12.37B | |
| -28.12% | 8.28B |
